[go: up one dir, main page]

WO2003006002A8 - Compositions et methodes d'administration d'agents de fixation a la tubuline dans le traitement de maladies oculaires - Google Patents

Compositions et methodes d'administration d'agents de fixation a la tubuline dans le traitement de maladies oculaires

Info

Publication number
WO2003006002A8
WO2003006002A8 PCT/US2002/022449 US0222449W WO03006002A8 WO 2003006002 A8 WO2003006002 A8 WO 2003006002A8 US 0222449 W US0222449 W US 0222449W WO 03006002 A8 WO03006002 A8 WO 03006002A8
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
compositions
methods
tubulin binding
binding agents
Prior art date
Application number
PCT/US2002/022449
Other languages
English (en)
Other versions
WO2003006002A1 (fr
WO2003006002A9 (fr
Inventor
David Sherris
Mark Wood
Original Assignee
Oxigene Inc
David Sherris
Mark Wood
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxigene Inc, David Sherris, Mark Wood filed Critical Oxigene Inc
Priority to IL15958102A priority Critical patent/IL159581A0/xx
Priority to CN028139917A priority patent/CN1527704B/zh
Priority to EP02756487A priority patent/EP1406600A4/fr
Priority to JP2003511808A priority patent/JP2004536847A/ja
Priority to CA2453442A priority patent/CA2453442C/fr
Priority to MXPA04000386A priority patent/MXPA04000386A/es
Priority to KR10-2004-7000464A priority patent/KR20040030042A/ko
Publication of WO2003006002A1 publication Critical patent/WO2003006002A1/fr
Priority to ZA2004/00210A priority patent/ZA200400210B/en
Publication of WO2003006002A8 publication Critical patent/WO2003006002A8/fr
Publication of WO2003006002A9 publication Critical patent/WO2003006002A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne l'administration d'agents de ciblage vasculaire, en particulier des agents de fixation à la tubuline, dans le traitement de la néovascularisation oculaire, des tumeurs oculaires, et des troubles tels que la rétinopathie diabétique, la rétinopathie de prématurité, le rétinoblastome et la dégénérescence maculaire.
PCT/US2002/022449 2001-07-13 2002-07-15 Compositions et methodes d'administration d'agents de fixation a la tubuline dans le traitement de maladies oculaires WO2003006002A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IL15958102A IL159581A0 (en) 2002-05-03 2002-07-15 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
CN028139917A CN1527704B (zh) 2001-07-13 2002-07-15 治疗眼病的组合物和微管蛋白结合剂用法
EP02756487A EP1406600A4 (fr) 2001-07-13 2002-07-15 Compositions et methodes d'administration d'agents de fixation a la tubuline dans le traitement de maladies oculaires
JP2003511808A JP2004536847A (ja) 2001-07-13 2002-07-15 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法
CA2453442A CA2453442C (fr) 2001-07-13 2002-07-15 Compositions et methodes d'administration d'agents de fixation a la tubuline dans le traitement de maladies oculaires
MXPA04000386A MXPA04000386A (es) 2001-07-13 2002-07-15 COMPOSICIONES Y MeTODOS PARA LA ADMINISTRACION DE AGENTES QUE SE UNEN A LA TUBULINA PARA EL TRATAMIENTO DE ENFERMEDADES OCULARES.
KR10-2004-7000464A KR20040030042A (ko) 2001-07-13 2002-07-15 안구 질환을 치료하기 위한 투불린 결합제 투여 조성물 및방법
ZA2004/00210A ZA200400210B (en) 2001-07-13 2004-01-12 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US38622701P 2001-07-13 2001-07-13
US60/386,227 2001-07-13
US37784502P 2002-05-03 2002-05-03
US37784702P 2002-05-03 2002-05-03
US37755602P 2002-05-03 2002-05-03
US60/377,845 2002-05-03
US60/377,847 2002-05-03
US60/377,556 2002-05-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/344,886 A-371-Of-International US20030181531A1 (en) 2001-07-13 2002-07-15 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
US10/732,680 Continuation-In-Part US20040229960A1 (en) 2001-07-13 2003-12-09 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases

Publications (3)

Publication Number Publication Date
WO2003006002A1 WO2003006002A1 (fr) 2003-01-23
WO2003006002A8 true WO2003006002A8 (fr) 2004-05-27
WO2003006002A9 WO2003006002A9 (fr) 2004-07-22

Family

ID=32034390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/022449 WO2003006002A1 (fr) 2001-07-13 2002-07-15 Compositions et methodes d'administration d'agents de fixation a la tubuline dans le traitement de maladies oculaires

Country Status (8)

Country Link
EP (1) EP1406600A4 (fr)
JP (2) JP2004536847A (fr)
KR (1) KR20040030042A (fr)
CN (1) CN1527704B (fr)
CA (1) CA2453442C (fr)
NZ (1) NZ575466A (fr)
WO (1) WO2003006002A1 (fr)
ZA (1) ZA200400210B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
JP4005048B2 (ja) * 2003-04-09 2007-11-07 日信工業株式会社 炭素繊維複合材料およびその製造方法
AU2010266109A1 (en) * 2009-07-02 2012-02-02 Oxigene, Inc. Combretastatins for prevention of posterior capsule opacification
WO2011022772A1 (fr) 2009-08-27 2011-03-03 Bionomics Limited Polythérapie pour traiter des maladies prolifératives
CN102596929A (zh) * 2009-08-27 2012-07-18 生物学特性有限公司 黄斑变性的治疗
AP2015008241A0 (en) * 2012-08-02 2015-01-31 Amril Ag Natural rubber containing nanocarbon
CN113577020B (zh) * 2021-08-16 2022-09-23 海南鑫开源医药科技有限公司 一种玻璃体腔内注射剂、其制备方法及应用
CN113520995B (zh) * 2021-08-16 2023-03-10 海南鑫开源医药科技有限公司 一种离子敏感型眼用原位凝胶、其制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338645C (fr) * 1987-01-06 1996-10-15 George R. Pettit Isolation, caracterisation structurelle et synthese de nouvelles substances antineoplastiques, appelees "combretastatines"
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
DE69942645D1 (en) * 1998-01-09 2010-09-16 Body Corporate Of The State Of Synthese von combretastatin a-4 prodrugs
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
WO2000048606A1 (fr) * 1999-02-18 2000-08-24 Oxigene, Inc. Compositions et procedes servant au ciblage de la destruction vasculaire
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts

Also Published As

Publication number Publication date
ZA200400210B (en) 2005-06-29
CA2453442A1 (fr) 2003-01-23
JP2009132738A (ja) 2009-06-18
CA2453442C (fr) 2011-02-01
WO2003006002A1 (fr) 2003-01-23
CN1527704A (zh) 2004-09-08
WO2003006002A9 (fr) 2004-07-22
NZ575466A (en) 2011-01-28
KR20040030042A (ko) 2004-04-08
CN1527704B (zh) 2011-05-18
EP1406600A1 (fr) 2004-04-14
JP2004536847A (ja) 2004-12-09
EP1406600A4 (fr) 2007-06-06

Similar Documents

Publication Publication Date Title
WO2002058730A3 (fr) Procedes et compositions pour le traitement de la neovascularisation oculaire et de lesions nerveuses
WO2007044668A3 (fr) Compstatine et analogues de celle-ci pour des troubles de la vue
WO2001051087A3 (fr) Nouveau traitement pour maladie des yeux
WO2003057259A3 (fr) Compositions de vert d'indocyanine et procedes d'utilisation correspondants
WO2007046083A3 (fr) Compositions pour le traitement de maladies oculaires
WO2006071548A3 (fr) Analogues d'aminopyrazine servant a traiter le glaucome et d'autres maladies ou etats medies par rho kinase
WO2005120461A3 (fr) Formulations liposomales renfermant de la dihydrosphingomyeline, et procedes d'utilisation correspondants
WO2003096990A3 (fr) Cages proteiques pour l'administration d'agents therapeutiques et d'imagerie medicale
WO2005002515A3 (fr) Administration de composes therapeutiques au cerveau et a d'autres tissus
WO2006055526A3 (fr) Compositions utiles pour le traitement de maladies neovasculaires oculaires et la degenerescence maculaire
WO2006059357A3 (fr) Utilisation de composes interferant avec la voie de signalisation hedgehog dans un medicament qui empeche, inhibe et/ou inverse des pathologies de l'oeil associees a une neovascularisation oculaire
WO2006096439A3 (fr) Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
WO2002070438A3 (fr) Compositions permettant l'administration de biophosphonates
WO2002087563A3 (fr) Compositions et procedes pour le traitement d'etats inflammatoires par des proteines ou polysaccharides contenant des agents anti-microtubules
WO2002064083A3 (fr) Synthese de 3-amino-thalidomide et de ses enantiomeres
WO2007049098A3 (fr) Formulations therapeutiques pour le traitement de maladies associees au beta-amyloide
WO2008054639A3 (fr) Réactifs et procédés de traitement de maladies et d'infections oculaires
WO2002009702A8 (fr) Methode de reduction de la pression intraoculaire avec des derives d'indole
WO2007075720A3 (fr) Preparations de mecamylamine topique pour administration oculaire et utilisations de celles-ci
WO2007056301A3 (fr) Thérapie avec un anticorps pour le traitement de maladies associées à l'intolérance au gluten
WO2003006002A8 (fr) Compositions et methodes d'administration d'agents de fixation a la tubuline dans le traitement de maladies oculaires
WO2008048675A3 (fr) Traitement de la dégénération maculaire due au vieillissement et d'autres maladies oculaires
WO2004016214A3 (fr) Methodes et compositions de traitement de troubles maculaires et retinaux
WO2007089673A8 (fr) Compositions et méthodes de traitement pour maladies et troubles ophtalmiques
TW200628473A (en) Novel heterocycles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US US US US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10344886

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 159581

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003511808

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002756487

Country of ref document: EP

Ref document number: 2004/00210

Country of ref document: ZA

Ref document number: 2453442

Country of ref document: CA

Ref document number: 20028139917

Country of ref document: CN

Ref document number: 530517

Country of ref document: NZ

Ref document number: 200400210

Country of ref document: ZA

Ref document number: 1020047000464

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1-2004-500060

Country of ref document: PH

Ref document number: PA/a/2004/000386

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002322494

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002756487

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 04/2003 UNDER (30) REPLACE "NOT FURNISHED, 13 JULY 2001 (13.07.2001), US" BY "60/386,227, 13 JULY 2001 (13.07.2001), US"; REPLACE "NOT FURNISHED, 3 MAY 2002 (03.05.2002), US" BY "60/377,847, 3 MAY 2002 (03.05.2002), US"

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

COP Corrected version of pamphlet

Free format text: PAGES 1/4-4/4, DRAWINGS, REPLACED BY NEW PAGES 1/4-4/4; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE